Avalo Therapeutics (AVTX) Competitors $8.93 +0.58 (+6.95%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$9.03 +0.10 (+1.13%) As of 08/8/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTX vs. AURA, ARCT, ABEO, NBTX, RNAC, RCKT, CADL, AMRN, INBX, and NGNEShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Aura Biosciences (AURA), Arcturus Therapeutics (ARCT), Abeona Therapeutics (ABEO), Nanobiotix (NBTX), Cartesian Therapeutics (RNAC), Rocket Pharmaceuticals (RCKT), Candel Therapeutics (CADL), Amarin (AMRN), Inhibrx Biosciences (INBX), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. Avalo Therapeutics vs. Its Competitors Aura Biosciences Arcturus Therapeutics Abeona Therapeutics Nanobiotix Cartesian Therapeutics Rocket Pharmaceuticals Candel Therapeutics Amarin Inhibrx Biosciences Neurogene Avalo Therapeutics (NASDAQ:AVTX) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Do analysts prefer AVTX or AURA? Avalo Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 235.95%. Aura Biosciences has a consensus price target of $22.00, indicating a potential upside of 223.53%. Given Avalo Therapeutics' higher possible upside, equities research analysts clearly believe Avalo Therapeutics is more favorable than Aura Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Is AVTX or AURA more profitable? Avalo Therapeutics' return on equity of -50.10% beat Aura Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -50.10% -35.76% Aura Biosciences N/A -58.63%-49.74% Which has more volatility and risk, AVTX or AURA? Avalo Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Do institutionals and insiders have more ownership in AVTX or AURA? 87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 3.0% of Avalo Therapeutics shares are owned by insiders. Comparatively, 5.4% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, AVTX or AURA? Avalo Therapeutics has higher revenue and earnings than Aura Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$440K219.80-$35.13MN/AN/AAura BiosciencesN/AN/A-$86.92M-$1.90-3.58 Does the media favor AVTX or AURA? In the previous week, Avalo Therapeutics had 2 more articles in the media than Aura Biosciences. MarketBeat recorded 4 mentions for Avalo Therapeutics and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.84 beat Avalo Therapeutics' score of -1.00 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAvalo Therapeutics beats Aura Biosciences on 7 of the 12 factors compared between the two stocks. Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.41M$2.42B$5.44B$9.61BDividend YieldN/A1.80%4.61%4.14%P/E RatioN/A20.5929.7624.84Price / Sales219.80698.88449.1298.65Price / CashN/A171.7436.4258.36Price / Book0.704.328.185.64Net Income-$35.13M$31.61M$3.26B$265.68M7 Day Performance13.18%0.46%6.88%4.95%1 Month Performance80.40%-0.33%1.00%0.83%1 Year Performance-16.39%5.35%28.85%22.18% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics2.6724 of 5 stars$8.93+6.9%$30.00+235.9%-17.5%$90.41M$440K0.0040News CoverageNegative NewsEarnings ReportGap UpAURAAura Biosciences1.9445 of 5 stars$6.61-1.9%$22.00+232.8%-19.7%$338.81MN/A-3.4850News CoverageUpcoming EarningsARCTArcturus Therapeutics2.7431 of 5 stars$12.20-0.8%$54.00+342.6%-36.6%$333.58M$152.31M-4.82180News CoverageUpcoming EarningsAnalyst UpgradeABEOAbeona Therapeutics3.8697 of 5 stars$6.42-1.1%$19.25+199.8%+40.0%$332.01M$3.50M-5.0690Upcoming EarningsNBTXNanobiotix0.3213 of 5 stars$6.80flat$8.00+17.6%+55.4%$320.51M$39.18M0.00100Gap UpHigh Trading VolumeRNACCartesian Therapeutics1.9546 of 5 stars$12.48+1.2%$40.00+220.5%-18.2%$320.02M$38.91M-0.2464News CoveragePositive NewsEarnings ReportRCKTRocket Pharmaceuticals4.8423 of 5 stars$3.07+2.7%$17.87+482.0%-85.0%$319.29MN/A-1.17240Trending NewsEarnings ReportAnalyst ForecastGap UpCADLCandel Therapeutics2.5226 of 5 stars$6.31+0.3%$22.00+248.7%+9.7%$315.15MN/A-4.7160Upcoming EarningsAMRNAmarin0.5567 of 5 stars$15.38+1.5%$12.00-22.0%+14.3%$313.92M$228.61M-4.19360INBXInhibrx Biosciences1.1954 of 5 stars$21.80+0.9%N/A+84.1%$312.68M$200K0.19166Upcoming EarningsNGNENeurogene2.8391 of 5 stars$21.72-0.3%$46.17+112.6%-41.9%$310.63M$925K-4.9990News CoverageGap Up Related Companies and Tools Related Companies Aura Biosciences Competitors Arcturus Therapeutics Competitors Abeona Therapeutics Competitors Nanobiotix Competitors Cartesian Therapeutics Competitors Rocket Pharmaceuticals Competitors Candel Therapeutics Competitors Amarin Competitors Inhibrx Biosciences Competitors Neurogene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTX) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
